(USNA) USANA Health Sciences - Overview

Sector: Consumer DefensiveIndustry: Packaged Foods | Exchange NYSE (USA) | Currency USD | Market Cap: 312m | Total Return -37.3% in 12m

Stock Supplements, Food, Skincare, Business Tools
Total Rating 40
Risk 87
Buy Signal -1.21
Packaged Foods -4.7
Personal Care Products -6.9
Market Cap: 312m
Avg Trading Vol: 2.66M USD
ATR: 4.40%
Peers RS (IBD): 16.7
Risk 5d forecast
Volatility39.8%
Rel. Tail Risk-9.62%
Reward TTM
Sharpe Ratio-0.98
Alpha-50.13
Character TTM
Beta0.941
Beta Downside1.067
Drawdowns 3y
Max DD75.10%
CAGR/Max DD-0.48
EPS (Earnings per Share) EPS (Earnings per Share) of USNA over the last years for every Quarter: "2021-03": 1.45, "2021-06": 1.87, "2021-09": 1.36, "2021-12": 1.03, "2022-03": 1.15, "2022-06": 1, "2022-09": 0.78, "2022-12": 0.66, "2023-03": 0.95, "2023-06": 0.89, "2023-09": 0.59, "2023-12": 0.87, "2024-03": 0.86, "2024-06": 0.54, "2024-09": 0.56, "2024-12": 0.64, "2025-03": 0.73, "2025-06": 0.74, "2025-09": -0.36, "2025-12": 0.6,
EPS CAGR: -15.93%
EPS Trend: -59.7%
Last SUE: 0.51
Qual. Beats: 0
Revenue Revenue of USNA over the last years for every Quarter: 2021-03: 307.976, 2021-06: 336.837, 2021-09: 274.352, 2021-12: 267.299, 2022-03: 272.867, 2022-06: 264.474, 2022-09: 233.3, 2022-12: 227.96, 2023-03: 248.36, 2023-06: 238.202, 2023-09: 213.365, 2023-12: 221.083, 2024-03: 227.8, 2024-06: 212.869, 2024-09: 200.221, 2024-12: 213.613, 2025-03: 249.539, 2025-06: 235.848, 2025-09: 213.67, 2025-12: 226.2,
Rev. CAGR: -4.88%
Rev. Trend: -54.2%
Last SUE: 0.04
Qual. Beats: 0
Risks
Technicals: choppy
Description: USNA USANA Health Sciences March 05, 2026

USANA Health Sciences, Inc. (USNA) manufactures and sells nutritional, personal care, and skincare products globally. The company operates in two segments: Direct Selling and Hiya Direct-To-Consumer.

Its product lines include nutritional supplements for various health needs, food products for weight management, and the Celavive skincare range. The direct selling business model is common in the nutritional supplement industry.

USANA distributes products through retail, subscriptions, direct selling, and online channels. They also engage in research collaborations, such as with Beijing University of Chinese Medicine.

For more detailed financial analysis, consider exploring ValueRays comprehensive reports.

Headlines to Watch Out For
  • Direct selling associate growth drives revenue
  • Asia Pacific sales performance impacts top line
  • Raw material and manufacturing costs affect margins
  • Regulatory changes in direct selling pose risk
Piotroski VR‑10 (Strict, 0-10) 7.0
Net Income: 10.8m TTM > 0 and > 6% of Revenue
FCF/TA: 0.01 > 0.02 and ΔFCF/TA -5.66 > 1.0
NWC/Revenue: 17.28% < 20% (prev 16.33%; Δ 0.94% < -1%)
CFO/TA 0.03 > 3% & CFO 22.3m > Net Income 10.8m
Net Debt (-144.4m) to EBITDA (95.0m): -1.52 < 3
Current Ratio: 2.24 > 1.5 & < 3
Outstanding Shares: last quarter (18.3m) vs 12m ago -4.20% < -2%
Gross Margin: 78.29% > 18% (prev 0.79%; Δ 7.75k% > 0.5%)
Asset Turnover: 124.1% > 50% (prev 114.2%; Δ 9.89% > 0%)
Interest Coverage Ratio: 65.70 > 6 (EBITDA TTM 95.0m / Interest Expense TTM 842k)
Altman Z'' 6.97
A: 0.22 (Total Current Assets 288.4m - Total Current Liabilities 128.6m) / Total Assets 742.9m
B: 0.63 (Retained Earnings 465.7m / Total Assets 742.9m)
C: 0.07 (EBIT TTM 55.3m / Avg Total Assets 745.6m)
D: 2.87 (Book Value of Equity 449.6m / Total Liabilities 156.6m)
Altman-Z'' Score: 6.97 = AAA
Beneish M -2.97
DSRI: 1.02 (Receivables 9.11m/8.22m, Revenue 925.3m/854.5m)
GMI: 1.01 (GM 78.29% / 79.43%)
AQI: 0.97 (AQ_t 0.48 / AQ_t-1 0.50)
SGI: 1.08 (Revenue 925.3m / 854.5m)
TATA: -0.02 (NI 10.8m - CFO 22.3m) / TA 742.9m)
Beneish M-Score: -2.97 (Cap -4..+1) = A
What is the price of USNA shares? As of March 30, 2026, the stock is trading at USD 16.92 with a total of 121,123 shares traded.
Over the past week, the price has changed by -2.65%, over one month by -21.38%, over three months by -14.24% and over the past year by -37.26%.
Is USNA a buy, sell or hold? USANA Health Sciences has received a consensus analysts rating of 3.00. Therefor, it is recommend to hold USNA.
  • StrongBuy: 0
  • Buy: 0
  • Hold: 1
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the USNA price?
ISSUER TARGET UP/DOWN
Wallstreet Target Price 39 130.5%
Analysts Target Price 39 130.5%
USNA Fundamental Data Overview March 29, 2026
P/E Trailing = 29.1724
P/E Forward = 8.4531
P/S = 0.3375
P/B = 0.5855
P/EG = 0.7046
Revenue TTM = 925.3m USD
EBIT TTM = 55.3m USD
EBITDA TTM = 95.0m USD
Long Term Debt = 5.65m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 14.0m USD (from shortTermDebt, last quarter)
Debt = 14.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -144.4m USD (from netDebt column, last quarter)
Enterprise Value = 167.9m USD (312.3m + Debt 14.0m - CCE 158.4m)
Interest Coverage Ratio = 65.70 (Ebit TTM 55.3m / Interest Expense TTM 842k)
EV/FCF = 19.69x (Enterprise Value 167.9m / FCF TTM 8.53m)
FCF Yield = 5.08% (FCF TTM 8.53m / Enterprise Value 167.9m)
FCF Margin = 0.92% (FCF TTM 8.53m / Revenue TTM 925.3m)
Net Margin = 1.16% (Net Income TTM 10.8m / Revenue TTM 925.3m)
Gross Margin = 78.29% ((Revenue TTM 925.3m - Cost of Revenue TTM 200.9m) / Revenue TTM)
Gross Margin QoQ = 88.77% (prev 73.45%)
Tobins Q-Ratio = 0.23 (Enterprise Value 167.9m / Total Assets 742.9m)
Interest Expense / Debt = 0.88% (Interest Expense 123k / Debt 14.0m)
Taxrate = 21.0% (US default 21%)
NOPAT = 43.7m (EBIT 55.3m * (1 - 21.00%))
Current Ratio = 2.24 (Total Current Assets 288.4m / Total Current Liabilities 128.6m)
Debt / Equity = 0.03 (Debt 14.0m / totalStockholderEquity, last quarter 533.1m)
Debt / EBITDA = -1.52 (Net Debt -144.4m / EBITDA 95.0m)
Debt / FCF = -16.93 (Net Debt -144.4m / FCF TTM 8.53m)
Total Stockholder Equity = 530.5m (last 4 quarters mean from totalStockholderEquity)
RoA = 1.44% (Net Income 10.8m / Total Assets 742.9m)
RoE = 2.03% (Net Income TTM 10.8m / Total Stockholder Equity 530.5m)
RoCE = 10.32% (EBIT 55.3m / Capital Employed (Equity 530.5m + L.T.Debt 5.65m))
RoIC = 8.10% (NOPAT 43.7m / Invested Capital 539.8m)
WACC = 8.92% (E(312.3m)/V(326.3m) * Re(9.29%) + D(14.0m)/V(326.3m) * Rd(0.88%) * (1-Tc(0.21)))
Discount Rate = 9.29% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -2.50%
[DCF] Terminal Value 72.07% ; FCFF base≈25.5m ; Y1≈21.4m ; Y5≈16.1m
[DCF] Fair Price = 21.58 (EV 253.8m - Net Debt -144.4m = Equity 398.2m / Shares 18.5m; r=8.92% [WACC]; 5y FCF grow -19.16% → 3.0% )
EPS Correlation: -59.65 | EPS CAGR: -15.93% | SUE: 0.51 | # QB: 0
Revenue Correlation: -54.16 | Revenue CAGR: -4.88% | SUE: 0.04 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.45 | Chg7d=+0.000 | Chg30d=+0.000 | Revisions Net=+1 | Analysts=1
EPS current Year (2026-12-31): EPS=2.00 | Chg7d=+0.000 | Chg30d=+0.000 | Revisions Net=+1 | Growth EPS=+3.6% | Growth Revenue=+1.9%
EPS next Year (2027-12-31): EPS=2.77 | Chg7d=+0.000 | Chg30d=+0.000 | Revisions Net=+1 | Growth EPS=+38.5% | Growth Revenue=+6.2%
Additional Sources for USNA Stock Fund Manager Positions: Dataroma · Stockcircle